DDInter517 DDInter1960
Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds.[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements.[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.[A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt. To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.
Dexbrompheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Dexbrompheniramine {u} (Compound) resembles {v} (Compound) Bepotastine
Dexbrompheniramine {u} (Compound) resembles {v} (Compound) Captodiame
Dexbrompheniramine {u} (Compound) binds {v} (Gene) KCNH2
Dexbrompheniramine {u} (Compound) downregulates {v} (Gene) IER3
Dexbrompheniramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Dexbrompheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Dexbrompheniramine {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Dexbrompheniramine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Dexbrompheniramine (Compound) resembles Bepotastine (Compound)
Dexbrompheniramine (Compound) resembles Captodiame (Compound)
Dexbrompheniramine (Compound) binds KCNH2 (Gene)
Dexbrompheniramine (Compound) downregulates IER3 (Gene)
Dexbrompheniramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid
Dexbrompheniramine may lead to a major life threatening interaction when taken with Potassium chloride
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine